Drug Trial Radar · NCT04198766
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
340
Planned (sponsor's estimate)
Start
Dec 10, 2019
Primary completion
Jul 2033
Study completion Jul 2033
Sponsor
- Lead sponsor
- Inhibrx Biosciences, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Conditions
- Solid Tumor
- Non-Small Cell Lung Cancer
- Head and Neck Cancer
- Melanoma
- Gastric Cancer
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibodyDrug
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
pembrolizumab 200 mgDrug
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
pembrolizumab 400 mgDrug
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Carboplatin AUC-5Drug
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4.
Carboplatin AUC-6Drug
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
Pemetrexed 500 mg/m2Drug
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Cisplatin 75mg/m2Drug
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
Paclitaxel 200mg/m2Drug
paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
Nab paclitaxel 100mg/m2Drug
Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4
Gemcitabine (1000 mg/m2)Drug
Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumabTime frame: ~2 years
- Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumabTime frame: ~2 years
- MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumabTime frame: ~2 years
- Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohortsTime frame: ~2 years
- Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLCTime frame: ~2 years
- To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)Time frame: ~2 years
Locations
60 sites in 4 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Active not recruiting
Oncura Health
Glendale, California · Recruiting
UC San Diego Health - Moores Cancer Center
La Jolla, California · Not yet recruiting
California Research Institute
Los Angeles, California · Recruiting
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California · Not yet recruiting
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
Valkyrie Clinical Trials
Murrieta, California · Recruiting
Providence Medical Foundation
Santa Rosa, California · Recruiting
Valkyrie Clinical Trials - Colorado
Lakewood, Colorado · Not yet recruiting
Clermont Oncology Center
Clermont, Florida · Recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida · Recruiting
Winship Cancer Institute - Emory University
Atlanta, Georgia · Active not recruiting
University of Illinois Cancer Center
Chicago, Illinois · Not yet recruiting
The University of Chicago Medical Center
Chicago, Illinois · Active not recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan · Completed
Henry Ford Cancer Institute
Detroit, Michigan · Recruiting
START Midwest
Grand Rapids, Michigan · Active not recruiting
HealthPartners Cancer Research Center
Saint Louis Park, Minnesota · Active not recruiting
HealthPartners Cancer Research Center (Regions Hospital)
Saint Paul, Minnesota · Completed
Washington University in St. Louis School of Medicine
St Louis, Missouri · Not yet recruiting
Intermountain Health Cancer Centers of Montana
Billings, Montana · Completed
Nebraska Cancer Specialists - Grand Island
Grand Island, Nebraska · Not yet recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
MD Anderson Cancer Center at Cooper
Camden, New Jersey · Not yet recruiting
Montefiore Medical Center
The Bronx, New York · Active not recruiting
Cleveland Clinic
Cleveland, Ohio · Active not recruiting
Providence Portland Medical Center
Portland, Oregon · Active not recruiting
Lehigh Valley Health Network
Allentown, Pennsylvania · Not yet recruiting
University of Tennessee Health Science Center
Knoxville, Tennessee · Not yet recruiting
Vanderbilt University School of Medicine
Nashville, Tennessee · Active not recruiting
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas · Completed
Renovatio Clinical - El Paso
El Paso, Texas · Completed
NEXT Oncology
San Antonio, Texas · Completed
Renovatio Clinical
The Woodlands, Texas · Completed
The University of Texas Health Science Center at Tyler
Tyler, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Completed
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Curie Oncology
Singapore, Singapore · Completed
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.